Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Theramex Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (18)
Cancellation by sponsor (18)
Prescription medicine registration (4)
Australian Public Assessment Report (AusPAR) (3)
Prescription medicine decision summary (2)
Prescription medicine evaluation (1)

Date

2024 (2)
2023 (5)
2022 (4)
2021 (11)
2020 (17)
2016 (1)
2011 (2)
2009 (1)
2007 (1)
2000 (2)

Results for "[search-keyword]"

Search

Sponsor content

46 result(s) found, displaying 21 to 30

Ovaleap

18 March 2021

Prescription medicine decision summary

TGA decision: Ovaleap (follitropin alfa) is approved to treat anovulatory infertility in woman who are unresponsive to clomiphene citrate.
OVALEAP (Theramex Australia Pty Ltd)

9 March 2021

Prescription medicine registration

Active ingredients: follitropin alfa.
Aventis Pharma Calcium Carbonate Tablet Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
aventis combination sachet Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
ACTONEL 35mg risedronate sodium 35mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
ACTONEL COMBI risedronate sodium 35mg and calcium carbonate 1250mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
ACTONEL COMBI D risedronate sodium 35mg tablet / supplemental 2500 mg calcium carbonate/22 microgram colecalciferol sachet composite pack Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
ACTONEL risedronate sodium 75 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
ATELVIA risedronate sodium 75 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd
ATELVIA ONCE-A-MONTH risedronate sodium 150 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

16 June 2020

Cancellation by sponsor

Requested by Theramex Australia Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.